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BAG-1M: A potential specificity determinant of corticosteroid the protein-folding activity of hsp70 through interaction
receptor action. BAG-1M is a eukaryotic cochaperone that with the amino- and carboxy-terminal domains of this
associates with several proteins, including the glucocorticoid protein [5, 6]. In this reaction, Hop establishes a physicalreceptor (GR). It down-regulates GR-mediated transactivation
link between hsp70 and hsp90 [7]. A protein termedby a mechanism that requires its prior recruitment by the li-
Hip (hsc70 interacting protein) has been identified as aganded receptor from cytoplasm into the nucleus. In the nu-
cleus, it uses a repeated sequence motif ([EEX4]8) at its NH2 chaperone cofactor interacting with the ATPase domain
terminus to inhibit DNA binding, as well as transactivation of hsc70 and prolonging the interaction of this protein
functions of the receptor. The mineralocorticoid receptor (MR), with various target substrates [8, 9].a structural and functional homologue of the GR, is unable to
Recently, another member in the family of chaperonestranslocate BAG-1M into the nucleus, and its transactivation
and cochaperones has been identified and termed Hap46,function is also not affected by this protein. This differential
regulation of GR and MR activity could be relevant in classic BAG-1M, or RAP46. Hap46/RAP46/BAG-1M interacts
mineralocorticoid tissues such as the kidney in which GR activ- with the amino-terminal adenosine 59-triphosphate
ity needs to be repressed to allow the MR to exert its action. (ATP)-binding domain of hsp70/hsc70 [10, 11] and com-In in situ hybridization studies, we show that BAG-1M is ex-
petes with Hop as well as Hip for binding to this molecu-pressed in the kidney. Its expression pattern, especially in the
lar chaperone [6, 12]. RAP46/BAG-1M also interactsdeveloping kidney, correlated well with that of the GR. We
therefore postulate that BAG-1M may be a specificity determi- with a number of steroid receptors, including the gluco-
nant in GR and MR action, and may feature prominently in corticoid receptor (GR) [13]. We have shown in transient
the control of GR activity in kidney development. overexpression studies in simian kidney COS-7 cells that
BAG-1M distinguishes between the action of the GR
and mineralocorticoid receptor (MR) [14]. Distinguish-
Glucocorticoid and mineralocorticoid function by ing between the action of the GR and MR is an important
binding to their respective receptors localized in the cyto- prerequisite for the physiological function of corticoste-
plasm of target cells in complex with the heat shock roids. In vivo, the circulating glucocorticoids bind both
proteins (hsp) hsp90, p60/Hop (hsp70/hsp90 organizing the GR and MR with high affinity, which prevents access
protein), hsp70, hsp40 and other chaperone molecules of mineralocorticoid to its own receptor. There is there-
[reviewed in 1]. These proteins, particularly hsp90, hsp70, fore the need for the action of the GR to be inactivated
and p60, keep the receptors in a state competent for in classic mineralocorticoid targets, which allows the MR
ligand binding [2]. Molecular chaperones of the hsp70/ to be functionally activated by its ligand. In the kidney or
hsc70 family play an important role in folding, transloca- colon, this is achieved by the enzyme 11b-hydroxysteroid
tion, and degradation of proteins in eukaryotic cells be- dehydrogenase, which inactivates glucocorticoids, allow-
cause of their ability to bind and stabilize non-native ing the mineralocorticoid aldosterone to get to its recep-
protein conformation [3, 4]. They recognize and bind tor [15, 16]. In addition, recent studies suggest that intra-
extended hydrophobic segments in substrates in a pro- cellular signaling pathways and certain cellular proteins
cess that allows denatured proteins to be bound and also distinguish between the action of the GR and the
released alternatively to effect protein folding. MR [17, 18].
Members of the hsp40 and p60/Hop families modulate In this communication, we describe experiments sug-
gesting that the eukaryotic cochaperone BAG-1M con-
tributes to the specificity of action of the MR in classicKey words: mineralocorticoid receptor, glucocorticoid receptor, eukar-
yotic cochaperone, BAG-1M, kidney development. mineralocorticoid tissues. This was demonstrated in tran-
sient transfection studies in COS-7 kidney cells in whichÓ 2000 by the International Society of Nephrology
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Table 1. Effect of BAG-1M on transactivation function of
glucocorticoid receptor–mineralocorticoid receptor chimeras







Presented is a compilation of the results of the effect of BAG-1M on transacti-
vation by different GR-MR chimeras [14, 26]. GGG and MMM stand for the
wild-type GR and MR. The first position of these three letter codes stands for
the N-terminal region, the DNA binding domain plus hinge region, and the
hormone binding domain. A chimera with the description MGG therefore stands
for a GR chimera with its NH2-terminal region replaced by an equivalent region
of the MR.
of several steroid hormone receptors, including the glu-
cocorticoid, androgen, and retinoic acid receptors [13,
14, 20, 25]. Of these, the action of the BAG-1 proteins
on the activity of the GR is the most intensively studiedFig. 1. Different isoforms of human BAG-1. The differently sized pro-
teins are all generated from the same mRNA and arose as a result of [13, 14] and will therefore be given further attention
the usage of alternative translation initiation sites. All three isoforms here.contain a ubiquitin-like domain (striped box) and an HSP70-binding
domain at their carboxy termini. BAG-1L and BAG-1M contain the
motif [EEX4]8, while BAG-1 contains two rather than eight copies of
BAG-1M INHIBITS GLUCOCORTICOIDthis sequence motif. A nuclear localization signal (gray box) is localized
at the N-terminus of BAG-1L. RECEPTOR ACTION
BAG-1M has been shown in transient transfection
studies in simian kidney cells to down-regulate the trans-
activation function of the GR [13]. In in vitro glutathi-BAG-1M down-regulated GR activity without any effect
on the action of the MR. Furthermore, in situ hybridiza- one-S-transferase pull-down assay, this protein inter-
acted with the GR through its hinge region (amino acidstion studies in the developing kidney provided additional
evidence of coexpression of BAG-1M and the GR but 491 to 515). This region of the receptor was also shown
to contribute to BAG-1M–mediated down-regulation ofnot the MR. Together, these findings strongly implicate
BAG-1M in the role of a specificity determinant of corti- the transactivation function of the receptor [13]. In in
vivo laser confocal immunofluorescence experiments,costeroid receptor action in the kidney.
BAG-1M colocalized in the cytoplasm with the GR, as
well as with its closely related structural homologue, the
BAG-1 ISOFORMS
MR. Hormone binding by these steroid receptors was,
At least three isoforms of BAG-1M exist (Fig. 1). however, not affected by BAG-1M [14]. Interestingly,
The largest isoform is BAG-1L, which arises through BAG-1M was recruited into the nucleus by only the
translation initiation at a noncannonical CTG codon up- liganded GR, where it down-regulated transactivation
stream and in-frame with an ATG used for the synthesis by this receptor. Transactivation by the MR was not
of BAG-1M. In addition, a smaller isoform (BAG-1) affected by BAG-1M, and neither did this receptor re-
exists that arises from a further downstream ATG site cruit BAG-1M into the nucleus [14]. This demonstrates
[19, 20]. These isoforms are collectively termed BAG-1 a differential regulatory effect of BAG-1M on the action
proteins in this article. of the GR and MR.
The BAG-1 proteins share a common carboxy-termi-
nal sequence through which they interact with hsp70
DOMAIN MAPPING WITH THE USE OFand its cognate hsc70 to inhibit their ability to renature
GR-MR CHIMERASdenatured proteins. The BAG-1 proteins are involved
in several other cellular processes. For example, they To determine why transactivation by the MR was not
affected by BAG-1M, chimeric GR-MR constructs wereinhibit apoptosis induced by several agents such as staur-
osporine [21] and growth factor withdrawal [22]. They cotransfected into COS-7 simian kidney cells, and their
transactivation function was measured in the presencealso alter the activity of the p53-inducible factor Siah-1
[23] and modulate cell motility of human gastric cancer of BAG-1M. The results of this study are summarized
in Table 1.cells [24]. In addition, they bind and modulate the activity
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Fig. 2. Expression of Bag-1 mRNA during kidney development. Kidneys at the indicated stages in mouse development were isolated, and whole-
mount in situ hybridization was performed (A–D). A 657 bp COOH-terminal EcoRI-NotI restriction fragment of mouse Bag-1 cDNA was
subcloned into pBluescript (Stratagene, La Jolla, CA, USA) and was used for in vitro transcription for antisense and sense control digoxygenin-
labeled RNA probes. The whole-mount in situ hybridization experiments were essentially performed as described by Belo et al [33]. Kidneys from
embryos at the stages indicated or adult (12 weeks old) kidney (pp) were isolated, fixed in 4% paraformaldehyde (PFA), and dehydrated, and 7
mm paraffin sections were subjected to radioactive in situ hybridization studies (E-H9). The same plasmid as indicated earlier in this article was
used for the generation of [35S]-labeled RNA probes and was used for hybridization as described by Hogan et al [34]. (A–D) Whole-mount in situ
hybridization. (E–H9) Radioactive in situ hybridizations on tissue sections. (E–H) Bright field illuminations. (E9–H9) Corresponding dark field
illuminations. (E) Embryonic day postcoitum. Abbreviations are: nb, newborn; pp, 12-weeks postpartum.
Transactivation by receptor constructs containing both When the first 70 NH2-terminal amino acids were de-
the hinge region and the hormone-binding domain (HBD) leted, the mutant BAG-1M was transported into the
such as the wild-type GR (GGG) or the chimera MGG nucleus but was nevertheless unable to inhibit GR action
was negatively regulated by BAG-1M [14]. BAG-1M [14]. The NH2-terminal amino acids of BAG-1M that
had no effect on transactivation by chimeric receptors mediate the negative regulatory function contain the se-
in which the hinge region and the HBD contain MR quence motif [EEX4]8. Partial deletion of this sequence
sequences such as the constructs MMM and GMM [14]. greatly reduced the ability of BAG-1M to inhibit trans-
No effect of BAG-1M was also observed when either activation by the GR [14]. Two lines of evidence further
one of these receptor domains contained MR sequences demonstrated the significance of the [EEX4]8 motif insuch as in constructs GGM or MMG [14]. These results inhibition of GR-mediated transactivation. First, trans-
show that both the hinge region and the HBD of the
activation by the GR was inhibited by BAG-1L, a larger
GR are required for BAG-1M to exert its negative action
isoform of BAG-1M that also contains the [EEX4]8 motif,on the transactivation function of the GR.
but not by the smaller isoform BAG-1 that lacks thisBAG-1M, on the other hand, is prevented from ex-
sequence [14]. Second, a fusion protein consisting of theerting its negative regulatory activities when its last 47
first 70 NH2-terminal amino acids of BAG-1M and ancarboxy-terminal amino acids are deleted [14]. Interest-
unrelated sequence exerted a strong dominant negativeingly, deletion of these amino acid sequences also pre-
action on transactivation by the GR [14]. This implicatesvented the recruitment of this protein into the nucleus
the possible involvement of a factor that interacts withby the GR [14], indicating that nuclear localization is
the [EEX4]8 motif for the down-regulation of the trans-essential for the negative regulatory function of BAG-
1M. However, nuclear transport alone is not sufficient. activation function of the GR.
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BIOLOGICAL SIGNIFICANCE and hind limbs, Meckel’s cartilage, cartilage primordia
of the ribs, cartilage rings of the trachea, cartilage pri-The biological significance of the negative regulatory
mordium of the orbitosphenoid bone as well as noncarti-action of BAG-1M is manifold. We have previously
laginous organs such as the thymus and kidney (resultsshown that BAG-1M–mediated inhibition of transactiva-
not shown). As the kidney is a classic mineralocorticoidtion by the GR correlated with inhibition of glucocorti-
target that expresses both the GR and MR, we examinedcoid-induced apoptosis [13]. We also observed that T cells
in detail the expression of BAG-1M in this organ.that are resistant to glucocorticoid-induced apoptosis ex-
BAG-1M expression in the kidney was detected bypress relatively high levels of BAG-1M [13]. Conversely,
whole-mount in situ hybridization as early as E13.5. Be-conditions that down-regulated the endogenous levels
tween this time and E17.5, BAG-1 was highly expressedof BAG-1M transcripts, such as exposure of thymoma
throughout all kidney cell types except the glomerulicells to the immunosuppressant rapamycin, enhanced
(Fig. 2). There was a progressive developmental restric-the transactivation potential of the GR and reduced GR-
tion of expression with time such that by E17.5 Bag-1Mmediated apoptosis [13]. As neoplastic cells generally
transcripts were detected in the convoluted and collect-express relatively high levels of BAG-1M [27, 28], our
ing tubules. Just before birth, no Bag-1M transcriptsresults on the inhibition of GR-mediated transactivation
were detected in the kidney, although they were againby this protein may provide mechanistic explanations for
detected in the adult kidney.the reported cases of glucocorticoid resistance in neo-
The expression pattern of BAG-1M in the kidney mir-plastic transformation. This point would have to be taken
rors that of the GR but is different from the expressioninto consideration in studies on glucocorticoid resistance
pattern of the MR. Convincing expression of the MR isin disorders such as acute lymphocytic and nonlympho-
observed by E18.5 and postnatally in the renal cortex [32],cytic leukemia [29, 30].
at which time BAG-1M expression is greatly reduced or
absent. Since BAG-1M protects cells against apoptosis,
BAG-1M EXPRESSION DURING it was of interest to compare the expression pattern of
DEVELOPMENT this protein with apoptosis in the kidney. Our results on
the expression of BAG-1M in the kidney did not corre-BAG-1M–mediated down-regulation of GR action
may also be relevant in the control of GR activity during late in time with apoptosis in this organ. Apoptosis in
the developing kidney is detected from E13 to E16, withdevelopment. Glucocorticoid levels and GR action need
to be controlled during embryogenesis because excess a gradual decrease by E18 [35]. From E18 to just before
birth, the number of apoptotic cells in the kidney wasglucocorticoid exposure and action of this hormone are
thought to be harmful to the developing fetus, reducing greatly reduced [35]. It is expected that an antiapoptotic
protein such as BAG-1M will show an increased expres-birth weight, and may even predispose to hypertension
in adulthood [31]. The level of glucocorticoid available sion at the latter stages of development and just after
birth. As the opposite pattern was observed (that is, lowto the fetus is thought to be controlled by placental
11b-hydroxysteroid dehydrogenase type 2. This enzyme expression in the late developmental stages), we suggest
that the role of BAG-1M in the developing kidney doesinactivates glucocorticoids and protects the developing
fetus from high maternal glucocorticoid levels [32]. An- not appear to oppose massive apoptosis, but most likely
protects against the deleterious effects of a functionallyother way whereby glucocorticoid action could be con-
trolled is through down-regulation of the action of the active GR. Knockout studies of this gene will prove the
suggested function of BAG-1M in development.GR during development. We therefore examined the
pattern of expression of the BAG-1 proteins during dif- In the adult kidney, where BAG-1, the MR, and GR
are all expressed, negative action of BAG-1M on trans-ferent stages of mouse embryogenesis to determine
whether it correlated with that of the GR. Using an activation by the GR but not MR will most likely contrib-
ute to the specificity of action of mineralocorticoid inantibody that detects all the different forms of BAG-1,
we identified BAG-1M as the most prominent, if not this organ.
the only, form of this family of proteins present during
Reprint requests to Dr. Andrew C.B. Cato, Forschungszentrum Karls-
different stages of mouse development (results not ruhe, Institute of Toxicology and Genetics, P.O. Box 3640, D-76021
Karlsruhe, Germany.shown). Based on this finding, we interpreted results we
E-mail: andrew.cato@itg.fzk.deobtained in in situ hybridization studies with a probe
that recognizes Bag-1 transcripts to be due to BAG-1M.
REFERENCESBAG-1M was detected as early as 10.5 embryonic
days postcoitum (E), with low but above background 1. Pratt WB, Dittmar KD: Studies with purified chaperones advance
the understanding of the mechanism of glucocorticoid receptor-expression in almost every tissue. However, certain tis-
hsp90 heterocomplex assembly. Trends Endocrinol Metab 5:244–
sues of cartilaginous origin showed exceptionally high 252, 1998
2. Dittmar KD, Pratt WB: Folding of the glucocorticoid receptorlevels of expression. These are the branchial arches, fore
Crocoll et al: BAG-1M in corticosteroid receptor action 1269
by the reconstituted hsp90-based chaperone machinery. J Biol 2-binding protein with anti-cell death activity. Cell 80:279–284,
1995Chem 272:13047–13054, 1997
3. Hartl FU: Molecular chaperones in cellular protein folding. Na- 22. Bardelli A, Longati P, Albero D, Goruppi S, Schneider C,
Ponzetto C, Comoglio PM: HGF receptor associates with theture 381:571–580, 1996
4. Rassow J, von Ahsen O, Bo¨mer U, Pfanner N: Molecular chaper- anti-apoptotic protein BAG-1 and prevents cell death. EMBO J
15:6205–6212, 1996ones: Towards a characterization of the heat-shock protein 70
family. Trends Cell Biol 7:129–133, 1997 23. Matsuzawa S-I, Takayama S, Froesch BA, Zapata JM, Reed JC:
p53-inducible human homologue of Drosophila seven in absentia5. Gebauer M, Zeiner M, Gehring U: Proteins interacting with the
molecular chaperone hsp70/hsc70: Physical associations and effects (Siah) inhibits cell growth: Suppression by BAG-1. EMBO J
17:2736–2747, 1998on refolding activity. FEBS Lett 417:109–113, 1997
6. Gebauer M, Zeiner M, Gehring U: Interference between proteins 24. Naishiro Y, Adachi M, Okuda H, Yawata A, Mitaka T, Taka-
yama S, Reed JC, Hinoda Y, Imai K: BAG-1 accelerates cellHap46 and Hop/p60, which bind to different domains of the molec-
ular chaperone hsp70/hsc70. Mol Cell Biol 18:6238–6244, 1998 motility of human gastric cancer cells. Oncogene 18:3244–3251,
19997. Johnson BD, Schumacher RJ, Ross ED, Toft DO: Hop modu-
lates hsp70/hsp90 interactions in protein folding. J Biol Chem 25. Lui R, Takayama S, Zheng Y, Froesch B, Chen G-Q, Xhang X,
Reed JC, Zhang X-K: Interaction of BAG-1 with retinoic acid273:3679–3686, 1998
8. Ho¨hfeld J, Minami Y, Hartl F-U: Hip, a novel cochaperone receptor and its inhibition of retinoic acid-induced apoptosis in
cancer cells. J Biol Chem 273:16985–16992, 1998involved in the eukaryotic hsc70/hsp40 reaction cycle. Cell 83:589–
598, 1995 26. Arriza JL: Aldosterone action: Perspectives from the cloning of
the mineralocorticoid receptor, in Aldosterone. Fundamental As-9. Frydman J, Ho¨hfeld J: Chaperones get in touch: The hip-hop
connection. Trends Biochem Sci 22:87–92, 1997 pects, edited by Bonvalet JP, Farman N, Lombe`s M, Rafestin-
Oblin M-E, Paris, John Libbey Eurotext Ltd., 1991, pp 13–2110. Takayama S, Bimston DN, Matsuzawa S-I, Freeman BC, Aime-
Sempe C, Xie Z, Morimoto RI, Reed JC: BAG-1 modulates the 27. Yang X, Chernenko G, Hao Y, Ding Z, Pater MM, Pater A,
Tang S-C: Human BAG-1/RAP46 protein is generated as fourchaperone activity of hsp70/hsc70. EMBO J 16:4887–4896, 1997
11. Stuart JK, Myszka DG, Joss L, Mitchell RS, McDonald SM, isoforms by alternative translation initiation and overexpressed in
cancer cells. Oncogene 17:981–989, 1998Xie Z, Takayama S, Reed JC, Ely KR: Characterization of interac-
tions between the anti-apoptotic protein BAG-1 and hsp70 molecu- 28. Takayama S, Krajewski S, Krajewska M, Kitada S, Zapata JM,
Kochel K, Knee D, Scudiero D, Tudor G, Miller GJ, Miyashitalar chaperones. J Biol Chem 273:22506–22514, 1998
12. Ho¨hfeld J, Jentsch S: GrpE-like regulation of the Hsc70 chaper- T, Yamada M, Reed JC: Expression and localization of Hsp70/
Hsc-binding anti-apoptotic protein BAG-1 and its variants in nor-one by the anti-apoptotic protein BAG-1. EMBO J 16:6209–6216,
1997 mal tissue and tumor cell lines. Cancer Res 58:3116–3131, 1998
29. Crabtree GR, Bloomfield CD, Smith KA, McKenna BA, Pe-13. Kullmann MJ, Schneikert J, Moll J, Heck S, Zeiner M, Gehring
U, Cato ACB: RAP46 is a negative regulator of glucocorticoid terson BA, Hildebrandt L, Munck A: Glucocorticoid receptors
and in vitro responses to glucocorticoid in acute nonlymphocyticreceptor action and hormone-induced apoptosis. J Biol Chem
273:14620–14625, 1998 leukemia. Cancer Res 41:4853–4856, 1981
30. Wells RJ, Mascaro K, Young PC, Provisor AJ, Cleary RE,14. Schneikert J, Hu¨bner S, Martin E, Cato ACB: A nuclear action
of the eukaryotic cochaperone RAP46 in downregulation of gluco- Baehner RL: Normal glucocorticoid receptor numbers in a child
with glucocorticoid-resistant relapsed acute lymphocytic leukemia.corticoid receptor activity. J Cell Biol 146:929–940, 1999
15. Edwards CRW, Stewart PM, Burt D, Brett L, McIntyre MA, Am J Pediatr Hematol Oncol 3:3–7, 1981
31. Edwards CRW, Benediktsson R, Lindsay RS, Seckl JR: Dys-Sutanto WS, Dekloet ER, Monder C: Localisation of 11b-
hydroxysteroid dehydrogenase-tissue specific protector of the min- function of placental glucocorticoid barrier: Link between fetal
environment and adult hypertension? Lancet 341:355–357, 1993eralocorticoid receptor. Lancet 2:986–989, 1988
16. Funder JW, Pearce PT, Smith R, Smith AI: Mineralocorticoid 32. Brown RW, Diaz R, Robson AC, Kotelevtsev Mullins JJ, Kauf-
man MH, Seckl JR: The ontogeny of 11b-steroid dehydrogenaseaction: Target tissue specificity is enzyme, not receptor, mediated.
Science 242:583–585, 1988 type 2 and mineralocorticoid receptor gene expression reveal intri-
cate control of glucocorticoid action in development. Endocrinol-17. Lim-Tio SS, Fuller PJ: Intracellular signaling pathways confer
specificity of transactivation by mineralocorticoid and glucocorti- ogy 137:794–797, 1996
33. Belo JA, Bouwmeester T, Leyns L, Kertesz NO, Gallo M,coid receptors. Endocrinology 139:1653–1661, 1998
18. Pearce D, Yamamoto KR: Mineralocorticoid and glucocorticoid Follettie M, De Robertis EM: Cerberus-like is a secreted factor
with neutralizing activity expressed in the anterior primitive endo-receptor activities distinguished by nonreceptor factors at a com-
posite response element. Science 259:1161–1165, 1993 derm of the mouse gastrula. Mech Dev 68:45–57, 1997
34. Hogan BLM, Beddington R, Costantini F, Lacy E: Manipulating19. Packham G, Brimmell M, Cleveland JL: Mammalian cells ex-
press two differently localized Bag-1 isoforms generated by alterna- the Mouse Embryo: A Laboratory Manual (2nd ed). Cold Spring
Harbor, Cold Spring Harbor Laboratory Press, 1994tive translation initiation. Biochem J 328:807–813, 1997
20. Froesch BA, Takayama S, Reed JC: BAG-1L protein enhances 35. Moser M, Pscherer A, Roth C, Becker J, Mu¨cher G, Zerres
K, Dixkens C, Weis J, Guay-Woodford L, Buettner R, Fa¨sslerandrogen receptor function. J Biol Chem 273:11660–11666, 1998
21. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, R: Enhanced apoptotic cell death of renal epithelial cells in mice
lacking transcription factor AP-2b. Genes Dev 11:1938–1948Reed JC: Cloning and functional analysis of BAG-1: A novel Bcl-
